

AN INDIVIDUALIZED APPROACH TO FLUID MANAGEMENT MAY IMPACT YOUR CLINICAL AND FINANCIAL OUTCOMES

In a retrospective, matched, single-center study of nearly 200 patients, researchers evaluated stroke volume (SV) guided resuscitation in ICU patients with **severe sepsis** and **septic shock** and found¹:



Sepsis is a key healthcare concern

MOST EXPENSIVE CONDITIONS TREATED IN U.S. HOSPITALS²



DID YOU KNOW? IV FLUIDS CAN CAUSE HARM ...

- Fluid is an independent predictor of mortality.^{7,*}
- Only ~50% of hemodynamically unstable patients will respond to IV fluid by increasing cardiac output and perfusion.⁸
- Assessing whether fluid may help or harm a patient is a critical step in optimizing treatment.

*From a retrospective study

- Sepsis is the body's life-threatening response to infection that can lead to tissue damage, organ failure, and death⁹
- Treatment includes IV fluids and medications
- In the U.S., 1.7 M cases of sepsis arise each year, resulting in 270 K deaths¹⁰
- Sepsis remains the most expensive reason for hospitalization, costing more than \$20B annually in the U.S.²
- Patients with Severe Sepsis admitted to the ICU have an average length of stay of approx. 7 days³
- Average ICU cost of sepsis per patient is between \$25,000-\$50,0004
- Increased sepsis bundle compliance is correlated with decreased sepsis mortality⁵
- Sepsis is a leading cause of hospital readmission⁶
- 20.4% of people hospitalized with sepsis are re-hospitalized within 30 days⁶

The solution: 100% non-invasive fluid management

UTILIZING STARLING TECHNOLOGY AS A TOOL MAY **HELP YOU IMPROVE SEP-1 COMPLIANCE^{*}**

- The Starling fluid management monitoring system is the only device that will allow your hospital to meet the reassessment of volume status and tissue perfusion of the 6-hour bundle, with a simple and easy to use nurse-driven PLR
- Works in mechanically ventilated and spontaneously breathing patients^{11,12}
- Not affected by vasoactive drugs or arrhythmias
- Moves seamlessly across the continuum of care: ED > ICU > OR > RRT > Floor

SIMPLIFIED USER INTERFACE

- Everything you need on one Home screen
- Flexibility to choose preferred view and parameters displayed on the screen

DYNAMIC ASSESSMENT: PLR/FLUID BOLUS

- Quickly get your Dynamic Assessment Results by seeing where the patient resides on the Starling Curve
- Option to end Dynamic Assessment as soon as patient's ∆SVI^{**} climbs ≥10%

Educational and training tools built into the monitor for easy access to training videos, clinical tools and quick guides

- * CMS data in combination with Baxter internal data on file
- ** Δ SVI = Change in Stroke Volume Index



Simplified User Interface



translocates 250-300 cc of blood from lower extremities into the heart, providing a reversible challenge of the heart's response to increased fluid load.

USE THE STARLING SYSTEM AND DYNAMIC ASSESSMENTS TO GUIDE YOUR FLUID DECISIONS

Hospital Reluctant to Give Fluid to CHF Patient

TOO LITTLE FLUID^{11,13} [HYPOVOLEMIA]

Possible complications: Tissue Hypoperfusion, Tissue Hypoxia, Organ Failure, Insufficient Perfusion

THE PATIENT



78 yo male from Skilled Nursing Facility arrived at the ED with hypotension, malaise. Work up for possible aspiration pneumonia.

- **PMHx:** CHF, Stage 3 Chronic Kidney Disease, IDDM

FLUIDS ADMINISTERED:

- Patient had received a 500 ml bolus from EMS
- 09:30am arrival to ED, 500 ml bolus infused. BP 91/47 (58), HR 105
- 10:30am: 250 ml ED bolus infused. BP 87/47(56). HR 107

Although the patient was still hypotensive, RN stated no plans for more IVF due to CHF and Kidney Disease.

The ED team decided not to guess whether the patient was fluid responsive, and a PLR was completed to assess if patient is fluid responsive:

- SVI increase of 15.7% indicated patient is fluid responsive.
- One liter of NS given, patient became normotensive in ED after infusion completed.

Checking for fluid responsiveness gave permission to give more fluids that were needed in this situation, when otherwise IVF may have been held.

FLUID VS COMPLICATIONS



Too Little Fluid^{13,14} [Hypovolemia]

> Studies show that giving too little or too much fluid can lead to serious complications and increased mortality.^{11,13-16}

Sepsis Patient is No Longer Fluid-Responsive

THE PATIENT



FLUIDS ADMINISTERED:

- BP 97/61

0

[Hypervolemia]

STARLING MONITORING INITIATED AT START OF 4TH LITER IVF:

CHECKING FOR FLUID RESPONSIVENESS ALLOWED THE CLINICAL **TEAM TO TITRATE FLUID ACCORDING TO PATIENT RESPONSE:**

- additional fluids

Results may vary from patient to patient.

TOO MUCH FLUID¹⁵⁻¹⁷ [HYPERVOLEMIA]

Possible complications: Tissue Edema, Organ Failure, Increased ICU/Ventilator Days, Increased Mortality



70 yo male presented to the ED with malaise and possible sepsis.

- Patient received 1 L NS from EMS and 2 L NS in ED.

- Lactic Acid: 5, Sepsis Protocol initiated.

- After the first 500 ml (of the 4th liter) a PLR was performed to assess whether the patient was fluid responsive.

- The patient's Δ SVI increased by 11%, which indicated that the patient was still fluid responsive.

- After 4th Liter infused, a second PLR was performed, which indicated that the patient was not fluid responsive $(\Delta SVI = 5\%)$, and therefore would not likely benefit from further IV fluids at this time.

- Fluids stopped and patient was admitted to hospital with a stable blood pressure 102/76.

- Give more fluids when the patient benefited from

- Stop giving additional fluids after 4 L and prevent potential complications associated with fluid overload





Utilizing Starling technology as a tool may help you improve SEP-1 compliance*

AVG SEP-1 COMPLIANCE RATES OF HOSPITALS UTILIZING STARLING TECHNOLOGY



There is a statistically significant correlation between Starling sensor usage and SEP-1 compliance!^{18,19}

*CMS data in combination with Baxter internal data on file

- SEP-1 is a Quality Measure issued by CMS, stipulating a protocol for the treatment of severe sepsis or septic shock patients.
- Your hospital SEP-1 compliance levels are now publicly reported at Medicare.gov **Hospital Compare:** medicare.gov/hospitalcompare/search.html
- Starling is the only device with demonstrated outcome data that will allow your hospital to meet the reassessment of volume status and tissue perfusion of the 6-hour bundle ... with a nurse-performed PLR!

SV-Guided Fluid Resuscitation May Translate To Clinical and Economic Benefits

In a retrospective, matched, single-center study of nearly 200 patients, researchers from the University of Kansas Health System assessed whether stroke volume (SV) guided resuscitation in 100 ICU patients improves outcomes in patients with severe sepsis and septic shock. Researchers found that implementing SV guided resuscitation was associated with improved patient outcomes which may also be associated with a reduction in cost of care.^{1,20}

FINANCIAL BUSINESS CASE

Variable	Starling Stroke Volume Fluid Therapy (n=100) ¹	Usual Care (Control, n=91) ¹	∆/p Value¹	Costs Assumptions*	Cost Avoidance*
ICU LOS (Days)	5.98 ± 0.68	8.87 ± 1.18	2.89 days <i>P</i> = 0.03	\$4,004/ICU day ²¹ \$906/floor day ²²	\$8,953
Fluid Balance (Liters)	1.77 L ± 0.60	5.36 L ± 1.01	3.59 L <i>P</i> = 0.002		
Pressor Use (Hours)	32.08 ± 5.22	64.86 ± 8.39	32.78 hours <i>P</i> = 0.001		
Mechanical Ventilation Initiated	29%	57%	RRR = 51% P = 0.0001	\$1,522/day ²³ 5.1 days ²²	\$1,940
Acute Dialysis Therapy Initiated	6.25%	19.5%	RRR = 32% P = 0.01	\$27,182 x (lc) (12.73 cases avoided/ 96 total patients) ²²	\$3,605
ESTIMATED SAVINGS PER TREATED PATIENT*					\$14.498

*Based upon supplemental data.

COST ASSUMPTIONS

ICU Length of Stay (LOS): 2.89 days x (\$4,004 [Avg ICU Day] - \$906 [Avg Floor Day]] = \$8,953 Mechanical Ventilation (MV): \$1,522 x 5.1 days x .25 = \$1,940 Assumes:

1. Incremental cost of MV \$1,522/day. 2. Average duration of MV in septic shock 5.1 days. 3. Assumes an absolute 25% reduction of patients receiving mechanical ventilation.

Acute Dialysis Therapy: \$27,182 (avg. dialysis-related hospital costs) x (12.73 cases avoided/96 total patients) = \$3,605

"By reducing length of stay, vasopressor use, and the requirement for mechanical ventilation using dynamic assessments provided by the Starling system, sepsis patients may benefit by an improved quality of care and reduced healthcare costs."

Dr. Steven Q. Simpson, Acting Director, Division of Pulmonary Disease and Critical Care Medicine at the University of Kansas Medical Center

REFERENCES

- 1. Latham H, et al. Stroke volume guided resuscitation in severe sepsis and septic shock improves outcomes. J Crit Care. 2017;28:42-46.
- 2. Pfuntner A (Truven Health Analytics), Wier LM (Truven Health Analytics), Steiner C (AHRQ). Costs for Hospital Stays in the United States, 2011. HCUP Statistical Brief #168. December 2013. Agency for Healthcare Research and Quality, Rockville, MD.
- 3. Mayr FB, et al. Proportion and cost of unplanned 30-day readmissions after sepsis compared with other medical conditions. *JAMA*. 2017;317:530-531.
- 4. Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. *Expert Rev Anti Infect Ther*. 2012;10(6):701-706.
- 5. Miller RR, et al. Multicenter implementation of a severe sepsis and septic shock treatment bundle. *Am J Respir Crit Care Med.* 2013; Jul 1;188(1):77-82.
- 6. Chang DW, et al. Rehospitalizations following sepsis: common and costly. Crit Care Med. 2015 Oct;43[10]:2085-2093.
- 7. Marik PE, et al. Fluid administration in severe sepsis and septic shock, patterns and outcomes: an analysis of a large national database. *Intensive Care Med.* 2017;43(5):625-632.
- 8. Bentzer P, et al. Will this hemodynamically unstable patient respond to a bolus of intravenous fluids? JAMA. 2016;316(12),1298.
- 9. Dantes, Lauren Epstein. Clinical Infectious Diseases, Volume 67, Issue 8, 15 October 2018, Pages 1300-1302.
- 10. Rhee C, Dantes R, Epstein Let al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009–2014. JAMA. 2017;318:1241–1249.
- 11. Duus N, Shogilev D, Skibsted S, et al. The reliability and validity of passive leg raise and fluid bolus to assess fluid responsiveness in spontaneously breathing emergency department patients. *J Crit Care.* 2015;30(1):217.e1-217.e5.
- 12. Raval et. al. Multicenter evaluation of noninvasive cardiac output measurement by bioreactance technique. *Journal of Clinical Monitoring and Computing*. 2008; Apr;22(2):113-119.
- 13. Rivers E, et al. Early goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-1377.
- 14. Mouncey PR. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372:1301-1311.
- 15. Kelm et al (2015)-Fluid overload in patients with severe sepsis and septic shock treated with early goal directed therapy is associated with increased acute need for fluid-related medical interventions and hospital death. *Shock.* 43:68-73.
- 16. Boyd J, et al. Vasopressin in Septic Shock Trial (VASST). Crit Care Med. 2011;39:259-265.
- 17. Vincent JL, et al. Sepsis in European ICU: Results of the SOAP Study. Crit Care Med. 2006;34:344-353.
- 18. Sahatjian J, et al. Incorporating routine passive leg raise (PLR) assessments improves sep-1 performance and patient care. *Chest.* 2019;165:A1675-A1676.
- 19. Sahatjian J, et al. Incorporating routine passive leg raise (PLR) assessments improves sep-1 performance and patient care. *ATS*. 2021.
- 20. Latham H et al. Sepsis Resuscitation Based On Stroke Volume Optimization Improves Outcome And Reduces Cost Of Care. Crit Care Med. 2018;(46):709.
- 21. Huynh T, et al. The frequency and cost of treatment perceived to be futile in critical care. *JAMA Internal Med.* 2013;173.
- 22. Premier Data Set, 2013. Premier, Inc.
- 23. Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: The contribution of mechanical ventilation. *Crit Care Med.* 2005;33(6):1266-1271.

Rx Only. For safe and proper use of product mentioned herein, please refer to the Instructions for Use or Operators Manual.

Baxter.com

Baxter International Inc. One Baxter Parkway/ Deerfield, Illinois 60015

Baxter and Starling are trademarks of Baxter International Inc. or its subsidiaries. Levophed is a trademark of Pfizer Inc. Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc., registered in the U.S. and other countries. Google Play and the Google Play logo are trademarks of Google Inc.

US-MD6-210069 V1 06/2021